| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000043511 |
| Receipt No. | R000049504 |
| Scientific Title | Confirmatory trial of narrower side margins for basal cell carcinoma in Japanese population (JCOG2005, J-BASE-MARGIN) |
| Date of disclosure of the study information | 2021/03/03 |
| Last modified on | 2021/03/03 (Ver. 1) |
| Basic information | ||
| Public title | Confirmatory trial of narrower side margins for basal cell carcinoma in Japanese
population (JCOG2005,J-BASE-MARGIN) |
|
| Acronym | Confirmatory trial of narrower side margins for basal cell carcinoma in Japanese
population (JCOG2005, J-BASE-MARGIN) |
|
| Scientific Title | Confirmatory trial of narrower side margins for basal cell carcinoma in Japanese
population (JCOG2005, J-BASE-MARGIN) |
|
| Scientific Title:Acronym | Confirmatory trial of narrower side margins for basal cell carcinoma in Japanese
population (JCOG2005, J-BASE-MARGIN) |
|
| Region |
|
|
| Condition | ||
| Condition | Head and neck basal cell carcinoma | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy and safety of excision with a narrower margin in patients with Japanese (Asian) primary basal cell carcinoma of the head and neck. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Phase III |
| Assessment | |
| Primary outcomes | 5-year local recurrence rate |
| Key secondary outcomes | Margin positivity rate (positive side-margin rate, positive deep-margin rate and both), adverse events |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | A:2-mm side margin for well-defined clinical border (+ reconstruction)
B: 3-mm side margin for poorly defined clinical border (+ reconstruction) |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Solitary head and neck basal cell carcinoma without treatment.
2) Diagnosed as basal cell carcinoma by incisional biopsy or dermoscopy image. 3) Basal cell carcinoma with a largest diameter between 3 mm to 20 mm. 4) No palpable, swollen regional lymph nodes (cN0, AJCC-TNM 8th edition). 5) Three or four grandparents of the patients are so-called yellow race. 6) Age >= 20 and =< 85 (male) and age >= 20 and =< 90 (female). 7) An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3. 8) No history of previous treatments including cryotherapy, electrocoagulation, curettage, or radiotherapy or imiquimod for basal cell carcinoma. 9) Adequate organ and marrow function as defined below within 28 days prior to registration: a) White blood cell >= 2,000 /mm3 b) Hemoglobin >= 7.5 g/dL c) Platelets >= 90,000 /mm3 d) Total bilirubin =< 4.0 mg/dL e) AST=< 100 IU/L f) ALT=< 100 IU/L g) Creatinine =< 1.8 mg/dL 10)Written informed consent. |
|||
| Key exclusion criteria | 1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or intramucosal tumors curatively treated with local therapy.
2) Active infection requiring systemic therapy. 3) Body temperature >= 38 degrees Celsius. 4) Women during pregnancy, within 28 days of postparturition, or during lactation. Men with favoring gestation of their partners. 5) Severe psychiatric disease. 6) Poorly controlled diabetes. 7) Poorly controlled hypertension. 8) History of unstable angina pectoris within 3 weeks or myocardial infarction within 6 months before registration. |
|||
| Target sample size | 410 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Saitama Medical University International Medical Center | ||||||
| Division name | Skin Oncology/Dermatology | ||||||
| Zip code | 350-1298 | ||||||
| Address | 1397-1 Yamane, Hidaka, Saitama, Japan | ||||||
| TEL | 042-984-4111 | ||||||
| JCOG_sir@ml.jcog.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | JCOG2005 Coordinating Office | ||||||
| Division name | Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center | ||||||
| Zip code | 350-1298 | ||||||
| Address | 1397-1 Yamane, Hidaka, Saitama, Japan | ||||||
| TEL | 042-984-4111 | ||||||
| Homepage URL | http://www.jcog.jp/ | ||||||
| JCOG_sir@ml.jcog.jp | |||||||
| Sponsor | |
| Institute | Japan Clinical Oncology Group (JCOG) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | National Cancer Center |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | National Cancer Center Institutional Review Board |
| Address | 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan |
| Tel | 03-3542-2511 |
| NCC_IRBoffice@ml.res.ncc.go.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 北海道大学病院(北海道)
旭川医科大学(北海道) 札幌医科大学(北海道) 筑波大学医学医療系(茨城県) 埼玉県立がんセンター(埼玉県) 埼玉医科大学国際医療センター(埼玉県) 埼玉医科大学病院(埼玉県) 国立がん研究センター中央病院(東京都) がん・感染症センター都立駒込病院(東京都) 慶應義塾大学病院(東京都) 東京大学医学部(東京都) 新潟県立がんセンター新潟病院(新潟県) 富山県立中央病院(富山県) 信州大学医学部(長野県) 静岡県立静岡がんセンター(静岡県) 名古屋大学医学部(愛知県) 京都大学医学部附属病院(京都府) 大阪国際がんセンター(大阪府) 国立病院機構九州がんセンター(福岡県) 福岡大学医学部(福岡県) 九州大学病院(福岡県) 熊本大学病院(熊本県) 国立病院機構鹿児島医療センター(鹿児島県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | Age-upper limit
male:85 years old <= female:90 years old >= |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049504 |